|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||0.00 - 0.00|
|Beta (5Y monthly)||0.26|
|PE ratio (TTM)||0.19|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
The FDA accepts Sarepta's (SRPT) regulatory filing seeking accelerated approval for SRP-9001, a gene therapy for DMD indication. A final decision is expected by May 2023.
Halozyme (HALO) is gaining on its proprietary drug delivery technology, ENHANZE. It expects strong revenues on the back of robust demand for its new partnered drugs.
Yahoo Finance's Julie Hyman breaks down leading business stories including news that Roche's potential Alzheimer's drug has failed, the Newman's Own Foundation CEO plans to retire amid a lawsuit, and Dolly Parton has received a $100 million award from Jeff Bezos to further her philanthropy.